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In a recent article, we found that Tribbles pseudokinase 3 (TRIB3) plays a tumor suppressor role and that this effect
relies on the dysregulation of the phosphorylation of v-akt murine thymoma viral oncogene homolog (AKT) by the
mammalian target of rapamycin complex 2 (mTORC2 complex), and the subsequent hyperphosphorylation and
inactivation of the transcription factor Forkhead box O3 (FOXO3).
Pseudokinases—a subgroup of protein
kinases that lack at least one of the con-
served catalytic residues present in the
kinase domain and therefore exhibit no
(or very low levels of) kinase activity1—
have been proposed to play critical roles as
activators of their specific targets 1. Like-
wise, their aberrant regulation has been
implicated in the etiology and progression
of a variety of diseases, including cancer.2
Tribbles pseudokinase-3 (TRIB3; also
named TRB3, NIPK, and SKIP3), which
belongs to the tribbles family of pseudoki-
nases, was first described in Drosophila as a
negative regulator of cell division in early
embryogenesis1 and has been proposed to
interact with different targets including
mitogen activated protein kinases
(MAPKs) and several transcription
factors3). TRIB3 has also been shown to
interact with and inhibit v-akt murine
thymoma viral oncogene homolog
(AKT),4 which has been suggested to sup-
press insulin signaling.
In our study,5 we investigated the effect
of genetic inactivation of TRIB3 in several
cellular and animal models of cancer. We
found that genetic inhibition of TRIB3
enhances tumorigenesis and that this
effect relies to a large extent on the ability
of this pseudokinase to regulate activity of
the AKT pathway. For example, we found
that loss of TRIB3 enhances the frequency
of malignant conversion of papillomas
generated in mice subjected to 7,12-dime-
thylbenz[a]anthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA)
treatment, and that loss of TRIB3
enhances the incidence of premalignant
and malignant lesions in phosphatase and
tensin homolog heterozygous (PtenC/¡)
mice. Likewise, genetic inhibition of
TRIB3 enhances proliferation, clonogenic-
ity, and the ability to generate tumor xen-
ografts of oncogene-transformed mouse
embryonic fibroblasts (MEFs) and of sev-
eral human cancer cell lines, with a paral-
lel increase in the phosphorylation of
AKT in samples derived from these
tumors. Together, these findings indicate
that genetic inhibition of TRIB3 enhances
tumorigenesis in several genetic contexts
and specifically in the presence of activat-
ing mutations of rat sarcoma virus onco-
gene (Hras) or deletion of one of the
copies of Pten. Nevertheless, other studies
have found that TRIB3 mRNA levels are
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increased in certain types of human can-
cer2,6 and have proposed that TRIB3 may
play an oncogenic role.7 Further research
should clarify whether inactivation or
enhanced expression of TRIB3 produces
different outcomes in distinct genetic or
cellular contexts.
Our findings indicate that the tumor
suppressive activity of TRIB3 relies on
its ability to limit the capacity of AKT
to become overactivated in response to
oncogenic signals. We found that
genetic inactivation of TRIB3 leads to
enhanced phosphorylation of Forkhead
box O3 (FOXO3) and BCL2-associated
agonist of cell death (BAD), but not of
other AKT substrates such as glycogen
synthase kinase 3 (GSK3) or AKT1
substrate 1 (AKT1S1; also named pro-
line rich AKT substrate or PRAS40),
suggesting that TRIB3 contributes to
the regulation of AKT selectivity for
some of its substrates. In line with this
idea, we have recently found that treat-
ment with D9-tetrahydrocannabinol
(THC, a compound derived from the
plant Cannabis sativa that exerts antitu-
mor effects in mouse models of can-
cer8,9) triggers AKT inhibition via
enhanced interaction of TRIB3 with
AKT and a subsequent decrease in the
interaction of AKT and TRIB3 with
the mTORC2 complex.10 These obser-
vations indicate that interaction with
TRIB3 negatively regulates AKT by
restricting access of the kinase to the
mammalian target of rapamycin com-
plex 2 (mTORC2 complex) and that,
through this mechanism, TRIB3 con-
tributes to the regulation of AKT selec-
tivity for some of its substrates (Fig. 1).
Another conclusion of our work is
that the mechanism underlying the
tumor suppressive activity of TRIB3
downstream of AKT relies at least in
part on the regulation of FOXO3
activity. In support of this idea, we
found that re-expression of a mutant
form of FOXO3 in which the residues
phosphorylated by AKT have been
mutated to Ala (FOXO-A3) abolished
the enhanced proliferation and clonoge-
nicity of TRIB3-deficient cells and
decreased the proliferation and growth
rate of tumors generated with these
cells. These observations support that
FOXO3 inactivation plays a crucial
role in the enhanced tumorigenic fea-
tures of cells in which Trib3 is geneti-
cally inactivated. Nevertheless,
expression of the FOXO-A3 mutant
did not modify the time to occurrence
of tumors derived from TRIB3-defi-
cient cells suggesting that, together
with the regulation of FOXO activity,
TRIB3 may use additional mechanisms
to control tumorigenesis.
In summary, our findings show that
genetic inhibition of TRIB3 increases
Figure 1. Putative mechanisms by which TRIB3 controls tumorigenesis. Tribble pseudokinase 3 (TRIB3) interacts with AKT, which regulates phosphoryla-
tion of the kinase by the mTORC2 complex (wild type). Genetic inhibition of TRIB3 in combination with different oncogenic signals facilitates hyperphos-
phorylation of AKT on Ser 473 by the mammalian target of rapamycin complex 2 (mTORC2 complex) and the subsequent hyperphosphorylation and
inactivation of the transcription factor Forkhead box O3 (FOXO3) and the BH3-only protein BCL2-associated agonist of cell death (BAD), but not that of
other AKT downstream targets. The hyperphosphorylation and inactivation of FOXO is, at least in part, responsible for the enhanced tumorigenic features
of TRIB3-deﬁcient cells.
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tumorigenesis in several animal models
of cancer and that this effect is due, at
least in part[AQ3], to enhanced
phosphorylation of AKT by the
mTORC2 complex and subsequent
hyperphosphorylation and inactivation
of FOXO3.
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